

## Dermatology References:

1. American Academy of Dermatology Association. Eczema Types: Atopic Dermatitis Symptoms. <https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/symptoms>. Accessed on September 11, 2020.
2. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol*. 2006;144(1):1-9.
3. Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116-132.
4. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol*. 2018;120:10-22.
5. Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. *Ann Allergy Asthma Immunol*. 2018;120(1):66-72.
6. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. *Ann Allergy Asthma Immunol*. 2018;121(3):340-347.
7. Silverberg JI, Gelfand JM, Margolis DJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. *Br J Dermatol*. 2019;181(3):554-565.
8. Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. *J Invest Dermatol*. 2015;135(1):56-66.
9. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. *Int J Dermatol*. 2012;51(10):1206-1212.
10. Bergqvist C, Ezzedine K. Vitiligo: A Review. *Dermatology*. 2020;236:571-592.
11. Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. *JAMA Dermatol*. 2022;158(1):43-50.
12. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Seminar: Vitiligo. *Lancet*. 2015;386:74-84.
13. Frisoli M, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. *Annu Rev Immunol*. 2020;38(1):621-648.
14. Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. *Br J Dermatol*. 2017;177(6):e338-e339.

15. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. *JAMA Dermatol.* 2013;149(2):159-164.
16. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. *J Eur Acad Dermatol Venereol.* 2018;32(8):1343-1351.
17. Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. *Br J Dermatol.* 2022;186(5):803-813. doi:10.1111/bjd.20969
18. National Organization for Rare Disorders. Prurigo Nodularis. <https://rarediseases.org/rare-diseases/prurigo-nodularis/>. Accessed on April 21, 2023.